Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 486 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical cream Clear all
Completed Phase 2 Interventional

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

NCT00883311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BRT-FC-83C
Device
Lead sponsor
Biomed Research & Technologies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional Results available

Treatment of Prepubertal Labial Adhesions

NCT02218463
View directory record Official record
Conditions
Prepubertal Labial Adhesions
Interventions
Estradiol cream 0.01%, Cetaphil
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 12 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis

NCT00667160
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
19
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

NCT05593445
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NCT03850483
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

NCT02534129
View directory record Official record
Conditions
Radiodermatitis
Interventions
Difinsa53, Aquaphor
Drug
Lead sponsor
ProTechSure Scientific, Inc.
Industry
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

NCT03983980
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tapinarof, Vehicle Cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 75 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
42
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

NCT03796052
View directory record Official record
Conditions
Ichthyosis, Pruritus
Interventions
Avena Sativa Skincare Regimen
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 18, 2026, 12:34 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

CeraVe Diabetes Mellitus

NCT04724967
View directory record Official record
Conditions
Diabetes Complications
Interventions
CeraVe Hydrating Cleanser, CeraVe Moisturizing Cream
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644
View directory record Official record
Conditions
Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing OTC Acne Treatment to Prescription Regimen

NCT01237821
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BenzaClin, Effaclar
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 18, 2026, 12:34 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

NCT03096444
View directory record Official record
Conditions
Pruritus
Interventions
Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream
Drug · Combination Product
Lead sponsor
Gil Yosipovitch
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

NCT01984775
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 cream, Vehicle cream, Positive control, Negative control
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thermosensitivity of a Topical Palmitated Formulation of Capsaicin

NCT05649228
View directory record Official record
Conditions
Pain Management
Interventions
Capsaicin 0.1% Cream, Capsaicin Palmitate 0.25% Cream, Placebo Cream
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Results available

Topical ASC-J9 Cream for Acne

NCT01289574
View directory record Official record
Conditions
Acne
Interventions
ASC-J9
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 18, 2026, 12:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03448939
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1, S5G4T-2
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 18, 2026, 12:34 PM EDT